grant · US

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health

AT A GLANCE

About this opportunity

National Institutes of Health lists this grant. The listed closing date is 19 Nov 2026. Check the official listing for details.

Who it’s for

Native American tribal organizations (other than Federally recognized tribal governments); Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); City or township governments; Special district governments; Public and State controlled institutions of higher education; State governments; County governments; Public housing authorities/Indian housing authorities; Small businesses; Private institutions of higher education; For profit organizations other than small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher…

Explore related listings

General information only, not advice. Govlark lists public opportunities that look relevant to the description given; it does not assess eligibility and does not say you qualify. Always read the official listing and guidelines before applying.

Source: US Government work (public domain) · Source: Grants.gov · Report an error